NCT00576979CompletedPhase 1/2
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Phase I-II Study of Escalating Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy in Combination With Etoposide (VP16) and Cytoxan as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Patients With Poor Risk Acute Lymphocytic Leukemia (ALL) or Poor Risk Acute Myelogenous Leukemia (AML)
Source: ClinicalTrials.gov · Last updated 24 Mar 2026
Brief summary (registry, in English)
RATIONALE: Giving intensity modulated radiation therapy (IMRT) and chemotherapy, such as etoposide and cyclophosphamide, before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving IMRT together with chemotherapy before transplant may stop this from happening. PURPOSE: This phase I/II trial is studying the side effects and best dose of intensity-modulated radiation therapy (IMRT) when given together with etoposide and cyclophosphamide followed by donor stem cell transplant and to see how well they work in treating patients with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- First submitted
- 18 Dec 2007
- Start date
- 4 Mar 2008
- Primary completion date
- 30 May 2016
- Lead sponsor
- City of Hope Medical Center
- NCT number
- NCT00576979
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 51
- From 4 Mar 2008 to the primary completion date, 30 May 2016
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiation therapy that would exclude the use of total-body irradiation
- Patients who have undergone bone marrow transplantation previously and who have relapsed
Other illness
- Patients with psychological or medical condition that patients physician deems unacceptable to proceed to allogeneic bone marrow transplant
Lab values
- Electrocardiogram (EKG) showing ischemic changes or abnormal rhythm and/or an echocardiogram or MUGA scan showing abnormal wall motion or ejection fraction \< 50%
Other
- Pregnancy
Who the study is looking for
- Patients with acute lymphocytic leukemia or acute myelogenous leukemia who are not in first or second remission (i.e., after failing remission induction therapy or in relapse or beyond second remission)
- All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical sibling who is willing to donate bone marrow or primed blood stem cells or a 10/10 allele matched unrelated donor; a single allele mismatch at A, B, C, DR, or DQ and a KIR mismatch at C will be allowed; all ABO blood group combinations of the donor/recipient are acceptable since even major ABO compatibilities can be dealt with by various techniques
- Prior therapy with VP-16, Busulfan, and Cytoxan is allowed
- A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of \>= 50% established by multi gated acquisition scan (MUGA) or echocardiogram
- Patients must have a serum creatinine of less than or equal to 1.2 or creatinine clearance \> 80 ml/min
- A bilirubin of less than or equal to 1.5
- Serum glutamic oxaloacetic transaminase (SGOT) less than 5 times the upper limit of normal
- Serum glutamate pyruvate transaminase (SGPT) less than 5 times the upper limit of normal
- Pulmonary functioning tests including diffusing capacity of carbon monoxide (DLCO) will be performed; forced expiratory volume in one second (FEV1) and DLCO should be greater than 50% of the predicted normal value
- The time from the end last induction or reinduction attempt should be \>= 14 days
- Signed informed consent form approved by the Institutional Review Board (IRB) is required
- DONOR: Any sibling donors who are histocompatible with the prospective recipient will be considered a suitable donor
- Donors will be excluded if for psychological or medical reasons they are unable to tolerate the procedure
- Donor should be able to donate peripheral blood stem cells or bone marrow
Age in the registry: 7 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| City of Hope Medical Center Coordinator of this site? Confirm its status | Duarte | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.